Review Article: Extending the Frontiers of Intestinal Ultrasound Knowledge, Performance and Expansion
Sizable gaps persist in the evidence base for IUS in IBD. Addressing these gaps through robust, multicentre studies and consensus-driven frameworks is essential to optimise the clinical and research utility of IUS in IBD management.
Authors
- Britt Christensen (ORCID: https://orcid.org/0000-0002-8746-4275)
- Michael T. Dolinger (ORCID: https://orcid.org/0000-0002-9023-4948)
- Bram Verstockt (ORCID: https://orcid.org/0000-0003-3898-7093)
- Cathy Lu (ORCID: https://orcid.org/0000-0003-3004-7048)
- Ryan E. Rosentreter
- Rune Wilkens (ORCID: https://orcid.org/0000-0002-4928-4708)
- Thomas M Goodsall (ORCID: https://orcid.org/0000-0002-4659-2422)
- F de Voogd (ORCID: https://orcid.org/0000-0003-4058-252X)
- Michael Winter (ORCID: https://orcid.org/0000-0003-0847-0448)
- Mariangela Allocca (ORCID: https://orcid.org/0000-0002-7204-1739)
- Maureen O’Brien
- Dan Carter (ORCID: https://orcid.org/0000-0001-7979-6803)
Institutions
- University of Copenhagen (DK)
- Dartmouth–Hitchcock Medical Center (US)
- The Royal Melbourne Hospital (AU)
- Vita-Salute San Raffaele University (IT)
- Tel Aviv University (IL)
- The University of Melbourne (AU)
- University of Calgary (CA)
- Sheba Medical Center (IL)
- John Hunter Hospital (AU)
- Bispebjerg Hospital (DK)
- Amsterdam Neuroscience (NL)
- Amsterdam University Medical Centers (NL)
- New York University (US)
- University of Newcastle Australia (AU)
- University of Amsterdam (NL)
- KU Leuven (BE)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1111/apt.70449
- Citations
- 3
- Primary Topic
- Gastrointestinal Bleeding Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.43
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Mylan
- Celltrion
- Samsung